Discover CMS's draft guidance on Medicare drug pricing, impacting stakeholders and beneficiaries, designed to streamline processes and enhance compliance.

Explore the proposed 2027 Medicare payment system changes, affecting outpatient services, drug pricing, and quality reporting. Learn about key impacts for providers.

Phil Perry's retirement signals notable changes in 340B litigation as CMS proposes a new rule impacting drug payments; public comment open through August 2026.

Explore the projected rise of Medicare costs for HIV treatment and the potential strategies to manage these expenses effectively.

The Trump administration proposes Medicare drug pricing reform aimed at reducing costs for patients and enhancing healthcare affordability. Read on for insights!

The new Medicare regulation aims to reduce drug costs for hospitals, predicting $1.1 billion in savings for beneficiaries. Learn more about this significant change.

The new HHS rule aims to cut drug prices for Medicare beneficiaries, targeting cost savings for hospitals in the 340B program while addressing billing concerns.

Explore a new legislative model aimed at capping prescription drug prices, enhancing state-funded insurance programs through public feedback and savings validation.

Explore how CMS is regulating Pharmacy Benefit Managers under CAA 2026, seeking feedback on compensation models and data reporting requirements. Act by July 20, 2026!

Explore the regulatory changes under the Trump administration affecting Medicaid and ACA, with implications for coverage accessibility and health care costs.